As of close of business last night, Biolife Solutions Inc’s stock clocked out at $17.60, down -1.68% from its previous closing price of $17.90. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 518550 shares were traded.
Ratios:
To gain a deeper understanding of BLFS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.83 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on July 11, 2023, initiated with a Buy rating and assigned the stock a target price of $29.
On April 25, 2022, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $28.
On October 19, 2021, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $61.B. Riley Securities initiated its Buy rating on October 19, 2021, with a $61 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 27 ’24 when Berard Todd sold 515 shares for $17.99 per share. The transaction valued at 9,265 led to the insider holds 139,644 shares of the business.
Mathew Aby J. sold 454 shares of BLFS for $8,167 on Mar 27 ’24. The EVP & Chief Scientific Officer now owns 319,682 shares after completing the transaction at $17.99 per share. On Mar 27 ’24, another insider, Foster Karen A., who serves as the Chief Quality and Operations of the company, sold 395 shares for $17.99 each. As a result, the insider received 7,106 and left with 159,145 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BLFS now has a Market Capitalization of 810.87M and an Enterprise Value of 801.87M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.56 while its Price-to-Book (P/B) ratio in mrq is 2.35. Its current Enterprise Value per Revenue stands at 5.60 whereas that against EBITDA is -17.73.
Stock Price History:
Over the past 52 weeks, BLFS has reached a high of $24.50, while it has fallen to a 52-week low of $8.92. The 50-Day Moving Average of the stock is 17.73, while the 200-Day Moving Average is calculated to be 15.50.
Shares Statistics:
It appears that BLFS traded 420.94K shares on average per day over the past three months and 408.29k shares per day over the past ten days. A total of 45.17M shares are outstanding, with a floating share count of 43.21M. Insiders hold about 4.62% of the company’s shares, while institutions hold 100.68% stake in the company. Shares short for BLFS as of Mar 15, 2024 were 3.03M with a Short Ratio of 7.21, compared to 3.55M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.70% and a Short% of Float of 10.13%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.31 for the current quarter, with a high estimate of -$0.13 and a low estimate of -$0.41, while EPS last year was -$0.32. The consensus estimate for the next quarter is -$0.24, with high estimates of -$0.11 and low estimates of -$0.34.
Analysts are recommending an EPS of between -$0.83 and -$1.28 for the fiscal current year, implying an average EPS of -$1.02. EPS for the following year is -$0.6, with 4 analysts recommending between -$0.48 and -$0.69.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $28.25M. It ranges from a high estimate of $33.7M to a low estimate of $20.9M. As of the current estimate, Biolife Solutions Inc’s year-ago sales were $37.7M, an estimated decrease of -25.10% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $26.6M, a decrease of -32.70% less than the figure of -$25.10% in the same quarter last year. There is a high estimate of $35.3M for the next quarter, whereas the lowest estimate is $21.9M.
A total of 7 analysts have provided revenue estimates for BLFS’s current fiscal year. The highest revenue estimate was $146.83M, while the lowest revenue estimate was $96M, resulting in an average revenue estimate of $114.62M. In the same quarter a year ago, actual revenue was $143.27M, down -20.00% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $143M in the next fiscal year. The high estimate is $173.1M and the low estimate is $114M. The average revenue growth estimate for next year is up 24.80% from the average revenue estimate for this year.
